Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT06030843

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Led by Chulalongkorn University · Updated on 2025-08-07

200

Participants Needed

1

Research Sites

95 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.

CONDITIONS

Official Title

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or more
  • Hospitalized for acute denovo or decompensated chronic heart failure regardless of ejection fraction
  • Acute kidney injury (KDIGO any stage) or urine NGAL ≥ 150 ng/mL
  • Able to enroll within 12 hours of AKI diagnosis or elevated urine NGAL detection
Not Eligible

You will not qualify if you...

  • Declined to participate in the study
  • Cardiogenic shock or unstable hemodynamics (systolic blood pressure < 100 mmHg or requiring inotropic support within last 24 hours)
  • Use of cardiac mechanical support devices (e.g., ECMO, intra-aortic balloon pump)
  • Acute coronary syndrome
  • AKI caused by conditions other than cardiorenal syndrome (e.g., sepsis, nephrotoxic injury, dehydration)
  • Anuria or dialysis requirement or expected dialysis within 24 hours
  • Baseline eGFR ≤ 20 ml/min/1.73m2 with or without dialysis
  • Heart or kidney transplant recipients
  • Use of any SGLT2 inhibitor in the last 3 months before admission
  • Allergy to SGLT2 inhibitors
  • Type 1 diabetes mellitus
  • History of ketoacidosis including diabetic ketoacidosis
  • Pregnancy
  • Comorbid conditions with life expectancy less than 1 month such as end-stage liver or heart disease or incurable malignancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Faculty of Medicine, Chulalongkorn University

Bangkok, Pathumwan, Thailand, 10330

Actively Recruiting

Loading map...

Research Team

S

Sasipha Tachaboon

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here